TY - JOUR AU - Deli, Mária Anna AU - Porkoláb, Gergő AU - Kincses, András AU - Mészáros, Mária AU - Szecskó, Anikó AU - Kocsis, Anna AU - Vigh, Judit Piroska AU - Valkai, Sándor AU - Veszelka, Szilvia AU - Walter, Fruzsina AU - Dér, András TI - Lab-on-a-chip models of the blood-brain barrier: evolution, problems, perspectives JF - LAB ON A CHIP J2 - LAB CHIP VL - 24 PY - 2024 IS - 5 SP - 1030 EP - 1063 PG - 34 SN - 1473-0197 DO - 10.1039/d3lc00996c UR - https://m2.mtmt.hu/api/publication/34673907 ID - 34673907 N1 - Funding Agency and Grant Number: National Research, Development and Innovation Office, Hungary [K-143766, K-124922, FK-143233, PD-138930, PD-143268]; Hungarian Research Network [SA-111/2021]; Centenarian Foundation; Talentum Foundation of Gedeon Richter Plc. [UNKP-23-3-SZTE-517, UNKP-23-3-SZTE-535]; National Academy of Scientist Education Program of the National Biomedical Foundation under Hungarian Ministry of Culture and Innovation; New National Excellence Program of the Hungarian Ministry of Culture and Innovation; [H-1103]; [19-21]; [UNKP-23-3-SZTE-497] Funding text: The following funding was received from the National Research, Development and Innovation Office, Hungary: grants K-143766 (to M. A. D.), K-124922 (to A. D.), FK-143233 (to S. V.), PD-138930 (to M. M.), PD-143268 (to A. K.). F. R. W. was supported by the grant SA-111/2021 from the Hungarian Research Network. M. M. was supported by the Centenarian Foundation, A. S. and J. P. V. by the Talentum Foundation of Gedeon Richter Plc. (H-1103 Budapest, Gyoemr & odblac;i str. 19-21. Hungary). G. P. was supported by the National Academy of Scientist Education Program of the National Biomedical Foundation under the sponsorship of the Hungarian Ministry of Culture and Innovation. The New National Excellence Program of the Hungarian Ministry of Culture and Innovation supported G. P. (UNKP-23-3-SZTE-497), A. S. (UNKP-23-3-SZTE-517), and J. P. V. (UNKP-23-3-SZTE-535). LA - English DB - MTMT ER - TY - JOUR AU - Mészáros, Mária AU - Phan, Thi Ha My AU - Vigh, Judit Piroska AU - Porkoláb, Gergő AU - Kocsis, Anna AU - Páli, Emese K. AU - Polgár, Tamás Ferenc AU - Walter, Fruzsina AU - Bolognin, Silvia AU - Schwamborn, Jens C. AU - Jan, Jeng-Shiung AU - Deli, Mária Anna AU - Veszelka, Szilvia TI - Targeting Human Endothelial Cells with Glutathione and Alanine Increases the Crossing of a Polypeptide Nanocarrier through a Blood–Brain Barrier Model and Entry to Human Brain Organoids JF - CELLS J2 - CELLS-BASEL VL - 12 PY - 2023 IS - 3 PG - 20 SN - 2073-4409 DO - 10.3390/cells12030503 UR - https://m2.mtmt.hu/api/publication/33621088 ID - 33621088 AB - Nanoparticles (NPs) are the focus of research efforts that aim to develop successful drug delivery systems for the brain. Polypeptide nanocarriers are versatile platforms and combine high functionality with good biocompatibility and biodegradability. The key to the efficient brain delivery of NPs is the specific targeting of cerebral endothelial cells that form the blood–brain barrier (BBB). We have previously discovered that the combination of two different ligands of BBB nutrient transporters, alanine and glutathione, increases the permeability of vesicular NPs across the BBB. Our aim here was to investigate whether the combination of these molecules can also promote the efficient transfer of 3-armed poly(l-glutamic acid) NPs across a human endothelial cell and brain pericyte BBB co-culture model. Alanine and glutathione dual-targeted polypeptide NPs showed good cytocompatibility and elevated cellular uptake in a time-dependent and active manner. Targeted NPs had a higher permeability across the BBB model and could subsequently enter midbrain-like organoids derived from healthy and Parkinson’s disease patient-specific stem cells. These results indicate that poly(l-glutamic acid) NPs can be used as nanocarriers for nervous system application and that the right combination of molecules that target cerebral endothelial cells, in this case alanine and glutathione, can facilitate drug delivery to the brain. LA - English DB - MTMT ER - TY - JOUR AU - Sipos, Bence AU - Bella, Zsolt AU - Gróf, Ilona AU - Veszelka, Szilvia AU - Deli, Mária Anna AU - Szűcs, Kálmán Ferenc AU - Sztojkov-Ivanov, Anita AU - Ducza, Eszter AU - Gáspár, Róbert AU - Kecskeméti, Gábor AU - Janáky, Tamás AU - Volk, Balázs AU - Budai-Szűcs, Mária AU - Ambrus, Rita AU - Révész, Piroska AU - Pannonhalminé Csóka, Ildikó AU - Katona, Gábor TI - Soluplus® promotes efficient transport of meloxicam to the central nervous system via nasal administration JF - INTERNATIONAL JOURNAL OF PHARMACEUTICS J2 - INT J PHARM VL - 632 PY - 2023 PG - 11 SN - 0378-5173 DO - 10.1016/j.ijpharm.2023.122594 UR - https://m2.mtmt.hu/api/publication/33547706 ID - 33547706 LA - English DB - MTMT ER - TY - JOUR AU - Veszelka, Szilvia AU - Mészáros, Mária AU - Porkoláb, Gergő AU - Rusznyák, Ágnes AU - Szászné Réti-Nagy, Katalin AU - Deli, Mária Anna AU - Vecsernyés, Miklós AU - Bácskay, Ildikó AU - Váradi, Judit AU - Fenyvesi, Ferenc TI - Effects of Hydroxypropyl-Beta-Cyclodextrin on Cultured Brain Endothelial Cells JF - MOLECULES J2 - MOLECULES VL - 27 PY - 2022 IS - 22 PG - 15 SN - 1420-3049 DO - 10.3390/molecules27227738 UR - https://m2.mtmt.hu/api/publication/33272291 ID - 33272291 N1 - Funding Agency and Grant Number: National Research, Development and Innovation Office, Budapest, Hungary [FK124634, NNE-29617, PD 138930]; National Research, Development and Innovation Fund of Hungary under the TKP2021-EGA funding scheme [TKP2021-EGA-18]; European Union and the European Regional Development Fund; National Academy of Scientist Education under Hungarian Ministry of Innovation and Technology [FEIF/646-4/2021-ITM_SZERZ]; StephenW. Kuffler Research Foundation; Gedeon Richter Plc. Centennial Foundation (Hungary); New National Excellence Program of the Ministry for Innovation and Technology from the National Research, Development and Innovation [UNKP-22-3-SZTE-446]; Gedeon Richter Plc. Centenarial Foundation (Hungary); Ministry of Human Resources [NTP-NFTO-22-B-0150]; National Talent Program; Premium Postdoctoral Research Program of the Hungarian Academy of Sciences [Premium-2019-469]; OTKA Young Researcher Excellence Program by the National Research, Development and Innovation Office of Hungary [OTKA-FK 143233]; [GINOP-2.3.4-15-2020-00008] Funding text: This study was supported by FK_17 (FK124634), and NNE-29617 (M-ERA.NET2 nanoPD) research grants of the National Research, Development and Innovation Office, Budapest, Hungary. Project no. TKP2021-EGA-18 was implemented with the support provided from the National Research, Development and Innovation Fund of Hungary, financed under the TKP2021-EGA funding scheme. The work is supported by the GINOP-2.3.4-15-2020-00008 project. The project is co-financed by the European Union and the European Regional Development Fund. G.P. was supported by the National Academy of Scientist Education under the sponsorship of the Hungarian Ministry of Innovation and Technology (FEIF/646-4/2021-ITM_SZERZ), the StephenW. Kuffler Research Foundation and the Gedeon Richter Plc. Centennial Foundation (H-1103 Budapest, Gyomroi str. 19-21. Hungary), as well as by the UNKP-22-3-SZTE-446 New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation. M.M. was supported by the research grant (PD 138930) of the National Research, Development and Innovation Office, Budapest, Hungary, the Gedeon Richter Plc. Centenarial Foundation (H-1103 Budapest, Gyomroi str. 19-21. Hungary), and the "National Talent Program" with the financial aid of the Ministry of Human Resources (NTP-NFTO-22-B-0150). S.V. was supported by the Premium Postdoctoral Research Program (Premium-2019-469) of the Hungarian Academy of Sciences, and the OTKA Young Researcher Excellence Program (OTKA-FK 143233) by the National Research, Development and Innovation Office of Hungary. AB - The application of 2-hydroxypropyl-beta-cyclodextrin (HPBCD) in the treatment of the rare cholesterol and lipid storage disorder Niemann–Pick disease type C opened new perspectives in the development of an efficient therapy. Even if the systemic administration of HPBCD was found to be effective, its low permeability across the blood–brain barrier (BBB) limited the positive neurological effects. Nevertheless, the cellular interactions of HPBCD with brain capillary endothelial cells have not been investigated in detail. In this study, the cytotoxicity, permeability, and cellular internalization of HPBCD on primary rat and immortalized human (hCMEC/D3) brain capillary endothelial cells were investigated. HPBCD shows no cytotoxicity on endothelial cells up to 100 µM, measured by impedance kinetics. Using a fluorescent derivative of HPBCD (FITC-HPBCD) the permeability measurements reveal that on an in vitro triple co-culture BBB model, FITC-HPBCD has low permeability, 0.50 × 10−6 cm/s, while on hCMEC/D3 cell layers, the permeability is higher, 1.86 × 10−5 cm/s. FITC-HPBCD enters brain capillary endothelial cells, is detected in cytoplasmic vesicles and rarely localized in lysosomes. The cellular internalization of HPBCD at the BBB can help to develop new strategies for improved HPBCD effects after systemic administration. LA - English DB - MTMT ER - TY - JOUR AU - Lee, Mei-Hwa AU - Jan, Jeng-Shiung AU - Thomas, James L. AU - Shih, Yuan-Pin AU - Li, Jin-An AU - Lin, Chien-Yu AU - Ooya, Tooru AU - Barna, Lilla AU - Mészáros, Mária AU - Harazin, András AU - Porkoláb, Gergő AU - Veszelka, Szilvia AU - Deli, Mária Anna AU - Lin, Hung-Yin TI - Cellular Therapy Using Epitope-Imprinted Composite Nanoparticles to Remove α-Synuclein from an In Vitro Model JF - CELLS J2 - CELLS-BASEL VL - 11 PY - 2022 IS - 16 PG - 13 SN - 2073-4409 DO - 10.3390/cells11162584 UR - https://m2.mtmt.hu/api/publication/33064300 ID - 33064300 N1 - Funding Agency and Grant Number: Ministry of Science and Technology of ROC [MOST 107-2923-M-006-002-MY3, MOST 107-2923-M-390-001-MY3, MOST 108-2221-E-006-034-MY3, MOST 108-2923-B-390-001-MY3, MOST 110-2221-E-390-003-MY3]; National Research, Development and Innovation Office, Budapest, Hungary [PD138930, NNE29617]; Kobe University grant for promoting international joint research; Gedeon Richter Plc Centenarial Foundation [H-1103]; Premium Postdoctoral Research Program of the Hungarian Academy of Sciences [Premium-2019-469]; Szeged Scientists Academy of the Hungarian Ministry of Innovation and Technology [FEIF/646-4/2021-ITM_SZERZ]; New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund [UNKP-21-3-405] Funding text: The authors would like to give their appreciation to the Ministry of Science and Technology of ROC under Contract nos. MOST 107-2923-M-006-002-MY3, MOST 107-2923-M-390-001-MY3, MOST 108-2221-E-006-034-MY3, MOST 108-2923-B-390-001-MY3, MOST 109-2221-E-214-028-and MOST 110-2221-E-390-003-MY3. This work was supported by a research grant of the National Research, Development and Innovation Office, Budapest, Hungary (NNE29617 to M.A.D.) in the frame of the nanoPD consortium, and partially supported by the Kobe University grant for promoting international joint research (to TO). M.M. was supported by the research grant of the National Research, Development and Innovation Office, Budapest, Hungary (PD138930) and the Gedeon Richter Plc Centenarial Foundation (H-1103 Budapest, Gyomr oi str. 19-21. Hungary). S.V. was supported by the Premium Postdoctoral Research Program (Premium-2019-469) of the Hungarian Academy of Sciences. G.P. was supported by the Szeged Scientists Academy under the sponsorship of the Hungarian Ministry of Innovation and Technology (FEIF/646-4/2021-ITM_SZERZ), as well as by the UNKP-21-3-405 New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund. AB - Several degenerative disorders of the central nervous system, including Parkinson’s disease (PD), are related to the pathological aggregation of proteins. Antibodies against toxic disease proteins, such as α-synuclein (SNCA), are therefore being developed as possible therapeutics. In this work, one peptide (YVGSKTKEGVVHGVA) from SNCA was used as the epitope to construct magnetic molecularly imprinted composite nanoparticles (MMIPs). These composite nanoparticles were characterized by dynamic light scattering (DLS), high-performance liquid chromatography (HPLC), isothermal titration calorimetry (ITC), Brunauer–Emmett–Teller (BET) analysis, and superconducting quantum interference device (SQUID) analysis. Finally, the viability of brain endothelial cells that were treated with MMIPs was measured, and the extraction of SNCA from CRISPR/dCas9a-activated HEK293T cells from the in vitro model system was demonstrated for the therapeutic application of MMIPs. LA - English DB - MTMT ER - TY - JOUR AU - Walter, Fruzsina AU - Harazin, András AU - Tóth, Andrea AU - Veszelka, Szilvia AU - Santa Maria, Anaraquel AU - Barna, Lilla AU - Kincses, András AU - Biczo, G AU - Balla, Zsolt AU - Kui, Balázs AU - Maléth, József AU - Cervenak, László AU - Tubak, Vilmos AU - Kittel, Ágnes AU - Rakonczay, Zoltán AU - Deli, Mária Anna TI - Blood–brain barrier dysfunction in l-ornithine induced acute pancreatitis in rats and the direct effect of l-ornithine on cultured brain endothelial cells JF - FLUIDS AND BARRIERS OF THE CNS J2 - FLUIDS BARRIERS CNS VL - 19 PY - 2022 IS - 1 PG - 20 SN - 2045-8118 DO - 10.1186/s12987-022-00308-0 UR - https://m2.mtmt.hu/api/publication/32667372 ID - 32667372 N1 - Institute of Biophysics, Biological Research Centre, Temesvári krt. 62, Szeged, 6726, Hungary Department of Medicine, University of Szeged, Kálvária sgt 57, Szeged, 6725, Hungary Department of Pathophysiology, University of Szeged, Semmelweis u. 1, Szeged, 6701, Hungary HAS-USZ Momentum Epithelial Cell Signaling and Secretion Research Group, University of Szeged, Dóm sqr. 10, Szeged, 6720, Hungary HCEMM-SZTE Molecular Gastroenterology Research Group, University of Szeged, Dóm sqr. 10, Szeged, 6720, Hungary Department of Internal Medicine and Hematology, Research Laboratory, Semmelweis University, Üllői út 26, Budapest, 1085, Hungary Creative Laboratory Ltd, Temesvári krt. 62, Szeged, 6726, Hungary Institute of Experimental Medicine, Eötvös Loránd Research Network, Szigony u. 43, Budapest, 1083, Hungary Wyss Institute for Biologically Inspired Engineering at Harvard University, 3 Blackfan Circle, Boston, MA 02115, United States Department of Biomedicine, Faculty of Health, Aarhus University, Høegh-Guldbergs Gade 10, Aarhus C, 8000, Denmark Institute of Applied Sciences, Department of Environmental Biology and Education, Juhász Gyula Faculty of Education, University of Szeged, Boldogasszony sgt. 6, Szeged, 6725, Hungary Cited By :1 Export Date: 23 November 2022 Correspondence Address: Deli, M.A.; Institute of Biophysics, Temesvári krt. 62, Hungary; email: deli.maria@brc.hu LA - English DB - MTMT ER - TY - JOUR AU - Veszelka, Szilvia AU - Mészáros, Mária AU - Porkoláb, Gergő AU - Szecskó, Anikó AU - Kondor, Nóra AU - Ferenc, Györgyi AU - Polgár, Tamás Ferenc AU - Katona, Gábor AU - Kóta, Zoltán AU - Kelemen, Lóránd AU - Páli, Tibor AU - Vigh, Judit Piroska AU - Walter, Fruzsina AU - Bolognin, Silvia AU - Schwamborn, Jens C. AU - Jan, Jeng-Shiung AU - Deli, Mária Anna TI - A Triple Combination of Targeting Ligands Increases the Penetration of Nanoparticles across a Blood-Brain Barrier Culture Model JF - PHARMACEUTICS J2 - PHARMACEUTICS VL - 14 PY - 2022 IS - 1 PG - 19 SN - 1999-4923 DO - 10.3390/pharmaceutics14010086 UR - https://m2.mtmt.hu/api/publication/32575627 ID - 32575627 LA - English DB - MTMT ER - TY - JOUR AU - Váczi, Sándor AU - Barna, Lilla AU - Harazin, András AU - Mészáros, Mária AU - Porkoláb, Gergő AU - Zvara, Ágnes AU - Ónody, Rita AU - Földesi, Imre AU - Veszelka, Szilvia AU - Penke, Botond AU - Fülöp, Lívia AU - Deli, Mária Anna AU - Mezei, Zsófia TI - S1R agonist modulates rat platelet eicosanoid synthesis and aggregation JF - PLATELETS J2 - PLATELETS VL - 33 PY - 2022 IS - 5 SP - 709 EP - 718 PG - 10 SN - 0953-7104 DO - 10.1080/09537104.2021.1981843 UR - https://m2.mtmt.hu/api/publication/32491017 ID - 32491017 AB - Sigma-1 receptor (S1R) is detected in different cell types and can regulate intracellular signaling pathways. S1R plays a role in the pathomechanism of diseases and the regulation of neurotransmitters. Fluvoxamine can bind to S1R and reduce the serotonin uptake of neurons and platelets. We therefore hypothesized that platelets express S1R, which can modify platelet function. The expression of the SIGMAR1 gene in rat platelets was examined with a reverse transcription polymerase chain reaction and a quantitative polymerase chain reaction. The receptor was also visualized by immunostaining and confocal laser scanning microscopy. The effect of S1R agonist PRE-084 on the eicosanoid synthesis of isolated rat platelets and ADP- and AA-induced platelet aggregation was examined. S1R was detected in rat platelets both at gene and protein levels. Pretreatment with PRE-084 of resting platelets induced elevation of eicosanoid synthesis. The rate of elevation in thromboxane B2 and prostaglandin D2 synthesis was similar, but the production of prostaglandin E2 was higher. The concentration-response curve showed a sigmoidal form. The most effective concentration of the agonist was 2 µM. PRE-084 increased the quantity of cyclooxygenase-1 as detected by ELISA. PRE-084 also elevated the ADP- and AA-induced platelet aggregation. S1R of platelets might regulate physiological or pathological functions. © 2021 Taylor & Francis Group, LLC. LA - English DB - MTMT ER - TY - JOUR AU - Akel, Hussein AU - Pannonhalminé Csóka, Ildikó AU - Ambrus, Rita AU - Bocsik, Alexandra AU - Gróf, Ilona AU - Mészáros, Mária AU - Szecskó, Anikó AU - Kozma, Gábor AU - Veszelka, Szilvia AU - Deli, Mária Anna AU - Kónya, Zoltán AU - Katona, Gábor TI - In Vitro Comparative Study of Solid Lipid and PLGA Nanoparticles Designed to Facilitate Nose-to-Brain Delivery of Insulin JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 22 PY - 2021 IS - 24 PG - 22 SN - 1661-6596 DO - 10.3390/ijms222413258 UR - https://m2.mtmt.hu/api/publication/32531953 ID - 32531953 N1 - Funding Agency and Grant Number: Ministry of Human Capacities, Hungary [TKP-2020]; National Research, Development and Innovation Office, HungaryNational Research, Development & Innovation Office (NRDIO) - Hungary [GINOP2.3.2-15-2016-00060] Funding text: The publication was founded by the Ministry of Human Capacities, Hungary (Grant TKP-2020), and by the National Research, Development and Innovation Office, Hungary (GINOP2.3.2-15-2016-00060) projects. LA - English DB - MTMT ER - TY - JOUR AU - Fekete, Tamás AU - Mészáros, Mária AU - Szegletes, Zsolt AU - Vizsnyiczai, Gaszton AU - Zimányi, László AU - Deli, Mária Anna AU - Veszelka, Szilvia AU - Kelemen, Lóránd TI - Optically Manipulated Microtools to Measure Adhesion of the Nanoparticle-Targeting Ligand Glutathione to Brain Endothelial Cells JF - ACS APPLIED MATERIALS & INTERFACES J2 - ACS APPL MATER INTER VL - 13 PY - 2021 IS - 33 SP - 39018 EP - 39029 PG - 12 SN - 1944-8244 DO - 10.1021/acsami.1c08454 UR - https://m2.mtmt.hu/api/publication/32156859 ID - 32156859 N1 - These authors contributed equally to this manuscript. (Tamás Fekete, Mária Mészáros) LA - English DB - MTMT ER -